Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250
There is some expectation that Eli Lilly's pipeline will break through, and analysts are particularly optimistic about diabetes and oncology treatments. Factors including these recent strong earnings, combined with a consensus Moderate Buy rating and a target price average of $1,002.22, constitute MarketBeat data.
Shares of Wells Fargo rose 3.9% after the San Francisco bank’s fourth-quarter profit of $1.43 a share beat expectations of $1 ...
Lilly gave hopeful income projections for 2025 ranging from $58 billion to $61 billion, therefore showing a midpoint rise of ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company ... The Recent Price Action ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
Both have added billions of dollars in additional revenue for these pharmaceutical leaders ... Over the last year, Eli Lilly’s stock is up a very respectable +25% which has roughly matched ...
Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback